Access Official Technical PDF

Share Summary:LinkedInEmail

Patent licensing disputes in complex technology markets often turn on how royalties are calculated, what evidence best reflects a patent portfolio’s value, and how FRAND commitments should be enforced. A 2019 amicus brief filed in the Ninth Circuit in the Federal Trade Commission’s case against Qualcomm offers a perspective on these questions. Its central argument is that patent valuation should not be reduced to a single formula: the smallest salable patent-practicing unit (SSPPU), established licensing rates, portfolio scope and the legal basis of a dispute all require context-sensitive analysis.

The brief represents the views of retired Federal Circuit Chief Judge Paul R. Michel, writing in support of Qualcomm. It is an advocacy document, not a court ruling. Its arguments nevertheless highlight issues that matter to technology businesses, standards participants and decision-makers assessing licensing practices.

What SSPPU does—and does not—mean

The SSPPU concept refers to the smallest product or component that practices a patent and can be sold separately. It arose in patent-damages cases as a way to help avoid jury confusion when an expert starts with the value of a complex product containing many patented and unpatented features.

The brief emphasizes that this is an evidentiary tool rather than a universal substantive rule. In its account of Federal Circuit precedent, SSPPU can help structure evidence in some damages cases, particularly jury trials, but does not require every royalty analysis to begin with a component-level price. The appropriate method depends on the evidence and the question being evaluated.

That distinction is important in industrial and technology supply chains. A product may contain numerous components, and a patent portfolio may cover a range of technologies. A component-level base may be useful in one analysis, while actual licenses or other market evidence may be more informative in another. The brief cautions against treating the smallest component as automatically decisive.

Patent licensing and the economics of portfolios

Commercial licenses frequently cover portfolios rather than a single patent. Parties may negotiate rights for a product line or class of products, rather than separately pricing every patent, claim and component. The brief argues that requiring a patent-by-patent and component-by-component calculation could increase transaction costs and make negotiations for large portfolios impractical.

In portfolio licensing, a royalty tied to a finished product can be a workable negotiated structure, according to the brief. That does not mean any chosen royalty base or rate is necessarily appropriate. Rather, the brief’s point is that the base should not be rejected solely because it is broader than the SSPPU. The royalty rate, the licensed rights, the portfolio’s scope and relevant market evidence must also be considered.

This distinction between negotiation practice and damages proof is useful for licensing teams. A method that helps a jury evaluate an expert’s damages model need not dictate how sophisticated businesses structure a voluntary agreement. Nor does a portfolio license automatically establish the value of every patent within it. The analysis still depends on the facts and the terms being assessed.

FRAND commitments and reasonable royalties

Standard-essential patent owners may make commitments to offer licenses on fair, reasonable and non-discriminatory (FRAND) terms. The brief describes FRAND as a contractual arrangement intended to support access to standardized technology while allowing innovators to obtain a return on their research and development. The terms of a commitment depend in part on the intellectual-property policies of the relevant standards-setting organization.

In the brief’s view, SSPPU should not be imported automatically into every FRAND analysis. It notes that FRAND policies do not necessarily specify a component-based royalty calculation, and that standards organizations may adopt differing policies. The practical implication is that parties should examine the actual commitment and governing policy rather than assume one valuation method applies in all cases.

The brief also points to established royalty evidence as an important consideration in determining a reasonable royalty. Actual licensing agreements can provide evidence of rates accepted in the marketplace and may reduce reliance on hypothetical assumptions. However, a court or decision-maker may need to assess whether the licenses are sufficiently comparable and account for differences in patents, products, parties and contractual terms. The brief argues that an established rate should not be disregarded without a reasoned analysis.

Choosing the right legal framework

A further argument in the brief concerns the boundary between contract, patent and antitrust law. It contends that a disagreement about whether a FRAND commitment has been met may often be addressed through contract or patent law, which can focus directly on contractual obligations or patent value. The brief warns against treating aggressive licensing conduct or a disputed royalty rate, by itself, as an antitrust violation.

This is the brief’s legal position, not a general resolution of how every FRAND dispute should be handled. For companies, the practical lesson is to distinguish among different questions:

  • Contract: What licensing commitment was made, and what does the relevant standards policy require?
  • Patent valuation: What rights are in force, what technology do they cover, and what evidence supports the proposed royalty?
  • Competition: Is there conduct that raises a distinct antitrust concern beyond a disagreement over licensing terms?

Keeping these issues separate can help commercial teams and counsel identify the evidence and remedies relevant to a dispute without assuming that one area of law answers every question.

Practical implications for licensing decisions

For technology developers, component suppliers, device manufacturers and standards participants, the brief underscores the value of documenting licensing rationale. Relevant records may include comparable agreements, portfolio scope, product coverage, the basis for the royalty structure and the terms of any FRAND commitment. Where a party relies on an established rate, explaining how the supporting licenses relate to the disputed portfolio and products is central to making that evidence meaningful.

For decision-makers reviewing a proposed royalty, the key is not to treat SSPPU, a product-level base or an existing license as conclusive in isolation. Each is a possible input. The analysis should consider how the method fits the licensing context, the evidence of market value and the legal obligations at issue.

Conclusion

The Ninth Circuit amicus brief presents a clear caution against turning SSPPU into a rigid rule for every patent valuation or FRAND negotiation. Its broader message is that patent licensing requires context: portfolio scale, actual market agreements, contractual commitments and the purpose of the valuation all matter. For industrial technology businesses, a disciplined approach means evaluating royalty evidence on its merits and identifying whether a disagreement is fundamentally contractual, patent-related or antitrust in nature.

Access Official Technical PDF

About The Author